Managing a portfolio of interdependent new product candidates in the pharmaceutical industry

被引:134
|
作者
Blau, GE [1 ]
Pekny, JF
Varma, VA
Bunch, PR
机构
[1] Purdue Univ, Dept Chem Engn, W Lafayette, IN 47908 USA
[2] Lilly Res Labs, Indianapolis, IN USA
关键词
D O I
10.1111/j.0737-6782.2004.00075.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Highly regulated industries such as pharmaceuticals and agrochemicals face the challenge of maintaining a Ocontinuous stream of new products. This is difficult because of low probabilities of technical success, high development costs, uncertain market impact, a scarcity of good new product ideas, and limited human and capital resources available to develop them. The problem of evaluating and selecting which new products to develop and then of sequencing or of scheduling them is complicated further by the presence of dependencies between products both in the market place and in the development process itself. This study proposes a portfolio management approach that selects a sequence of projects, which maximizes the expected economic returns at an acceptable level of risk for a given level of resources in a new product development pipeline. A probabilistic network model of distinct activities is used to capture all the activities and resources required in the "process" of developing a new drug. A prioritization scheme suggesting sequences for developing new independent drug candidates with unlimited resources is generated with a conventional bubble chart approach. These sequences initiate a genetic algorithm (GA)-based search for the optimal sequence in the presence of product dependencies and limited resources. By statistically evaluating the sequences generated during the GA search using a discrete event simulation model, it is possible to construct an economic reward-risk frontier that illustrates the trade-offs between expected rewards and risks. The model ideally is suited to answer various "what if" questions relative to changes in the resource level on pipeline performance. The methodology is illustrated with an industrially motivated case study, involving nine interdependent new product candidates targeting three diseases. The dramatic results yield a candidate sequence with an expected return 28 percent higher than the sequence suggested by the bubble chart approach at almost the same level of risk. The synergism among the candidate dependencies, pipeline resources, and economic and technical uncertainties demonstrates the necessity of a computationally intensive approach if the best development strategy is to be realized.
引用
收藏
页码:227 / 245
页数:19
相关论文
共 50 条
  • [31] Gamifying the Product Quality Reviews in the Pharmaceutical Industry
    Marcao, Ricardo Pateiro
    Pestana, Gabriel
    Sousa, Maria Jose
    PROCEEDINGS OF THE 20TH EUROPEAN CONFERENCE ON KNOWLEDGE MANAGEMENT (ECKM 2019), VOLS 1 AND 2, 2019, : 724 - 731
  • [32] Product-Service System for the Pharmaceutical Industry
    Salwin, Mariusz
    Kraslawski, Andrzej
    Andrzejewski, Michal
    Lipiak, Jan
    SMART AND SUSTAINABLE COLLABORATIVE NETWORKS 4.0 (PRO-VE 2021), 2021, 629 : 485 - 493
  • [33] Managing the pharmaceutical industry-health system interface
    Zarowitz, BJ
    Muma, B
    Coggan, P
    Davis, G
    Barkley, GL
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (12) : 1661 - 1668
  • [34] Medical Education and the Pharmaceutical Industry: Managing an Uneasy Alliance
    Michael D. Jibson
    Academic Psychiatry, 2006, 30 : 36 - 39
  • [35] Managing generic competition and patent strategies in the pharmaceutical industry
    Whitehead, Brian
    Jackson, Stuart
    Kempner, Richard
    JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2008, 3 (04) : 226 - 235
  • [36] MANAGING LABORATORY AUTOMATION IN A CHANGING PHARMACEUTICAL-INDUSTRY
    RUTHERFORD, ML
    JOURNAL OF AUTOMATIC CHEMISTRY, 1995, 17 (02): : 59 - 63
  • [37] Managing supply chain uncertainty and risk in the pharmaceutical industry
    Wang, Michael
    Jie, Ferry
    HEALTH SERVICES MANAGEMENT RESEARCH, 2020, 33 (03) : 156 - 164
  • [38] Medical education and the pharmaceutical industry: Managing an uneasy alliance
    Jibson, MD
    ACADEMIC PSYCHIATRY, 2006, 30 (01) : 36 - 39
  • [39] Managing product variety: A study of the bicycle industry
    Fisher, M
    Randall, T
    Reibstein, D
    Ulrich, K
    PROCEEDINGS OF THE 1996 MSOM CONFERENCE, 1996, : 189 - 194
  • [40] Portfolio management: A new approach for managing IT assets
    Paul, RA
    24TH ANNUAL INTERNATIONAL COMPUTER SOFTWARE AND APPLICATIONS CONFERENCE (COSPSAC 2000), 2000, 24 : 79 - 83